Hypoglycemic Agents

"Hypoglycemic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Substances which lower blood glucose levels.

Descriptor ID	D007004
MeSH Number(s)	D27.505.696.422
Concept/Terms	Hypoglycemic Agents Hypoglycemic Agents Agents, Hypoglycemic Antihyperglycemics Antihyperglycemic Agents Agents, Antihyperglycemic Hypoglycemic Drugs Drugs, Hypoglycemic Hypoglycemics Hypoglycemic Effect Hypoglycemic Effect Effect, Hypoglycemic Hypoglycemic Effects Effects, Hypoglycemic Antidiabetics Antidiabetics Antidiabetic Drugs Drugs, Antidiabetic Antidiabetic Agents Agents, Antidiabetic

Below are MeSH descriptors whose meaning is more general than "Hypoglycemic Agents".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Physiological Effects of Drugs [D27.505.696]
Hypoglycemic Agents [D27.505.696.422]

Below are MeSH descriptors whose meaning is more specific than "Hypoglycemic Agents".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Hypoglycemic Agents" by people in this website by year, and whether "Hypoglycemic Agents" was a major or minor topic of these publications.

Bar chart showing 173 publications over 29 distinct years, with a maximum of 20 publications in 2017

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	1	0	1
1998	0	1	1
1999	1	2	3
2000	1	1	2
2001	0	1	1
2002	1	0	1
2003	1	2	3
2004	4	0	4
2005	3	1	4
2006	1	2	3
2007	6	2	8
2008	7	1	8
2009	3	3	6
2010	6	4	10
2011	4	4	8
2012	2	4	6
2013	4	4	8
2014	2	4	6
2015	6	1	7
2016	5	1	6
2017	15	5	20
2018	11	2	13
2019	6	4	10
2020	3	3	6
2021	1	7	8
2022	0	8	8
2023	1	4	5
2024	3	3	6
2025	1	0	1

Below are the most recent publications written about "Hypoglycemic Agents" by people in Profiles.

LaRovere KL, Asaro LA, Coughlin-Wells K, Nadkarni VM, Agus MSD. Blood Glucose Range for Hyperglycemic PICU Children With Primary Neurologic Diagnoses: Analysis of the Heart and Lung Failure-Pediatric Insulin Titration (HALF-PINT) Trial. Pediatr Crit Care Med. 2025 Apr 01; 26(4):e432-e446.

View in: PubMed
Amaral DC, Guedes J, Cruz MRB, Cheidde L, Nepomuceno M, Magalh?es PLM, Brazuna R, Mora-Paez DJ, Huang P, Razeghinejad R, Schuman JS, Myers JS. GLP-1 Receptor Agonists Use and Incidence of Glaucoma: A Systematic Review and Meta-Analysis. Am J Ophthalmol. 2025 Mar; 271:488-497.

View in: PubMed
Simonson DC, Testa MA, Ekholm E, Su M, Vilsb?ll T, Jabbour SA, Lind M. Continuous Glucose Monitoring Profiles and Health Outcomes After Dapagliflozin Plus Saxagliptin vs Insulin Glargine. J Clin Endocrinol Metab. 2024 11 18; 109(12):e2261-e2272.

View in: PubMed
Orbell SL, Codario RA, Zupa MF, Estock JL. Severe Insulin Pump-Related Adverse Events: Potential Root Causes and Impact of the COVID-19 Pandemic. J Diabetes Sci Technol. 2025 11; 19(6):1614-1623.

View in: PubMed
Jabbour S, Paik JS, Aleppo G, Sharma P, Gomez Valderas E, Benneyworth BD. Switching to Tirzepatide 5?mg From Glucagon-Like Peptide-1 Receptor Agonists: Clinical Expectations in the First 12 Weeks of Treatment. Endocr Pract. 2024 Aug; 30(8):701-709.

View in: PubMed
Wai KM, Mishra K, Koo E, Ludwig CA, Parikh R, Mruthyunjaya P, Rahimy E. Impact of GLP-1 Agonists and SGLT-2 Inhibitors on Diabetic Retinopathy Progression: An Aggregated Electronic Health Record Data Study. Am J Ophthalmol. 2024 09; 265:39-47.

View in: PubMed
Perez AM, Neag E, Sridhar J, Williams BK. Weight loss, bariatric surgery, and novel antidiabetic drugs effects on diabetic retinopathy: a review. Curr Opin Ophthalmol. 2024 May 01; 35(3):192-196.

View in: PubMed
Estock JL, Codario RA, Zupa MF, Keddem S, Rodriguez KL. Insulin Pump Alarms During Adverse Events: A Qualitative Descriptive Study. J Diabetes Sci Technol. 2025 05; 19(3):739-748.

View in: PubMed
Zinter MS, Markovic D, Asaro LA, Nadkarni VM, McQuillen PS, Sinha P, Matthay MA, Jeschke MG, Agus MSD, Sapru A. Tight Glycemic Control, Inflammation, and the ICU: Evidence for Heterogeneous Treatment Effects in Two Randomized Controlled Trials. Am J Respir Crit Care Med. 2023 04 01; 207(7):945-949.

View in: PubMed
Lin TY, Kang EY, Shao SC, Lai EC, Garg SJ, Chen KJ, Kang JH, Wu WC, Lai CC, Hwang YS. Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists. Diabetes Metab J. 2023 05; 47(3):394-404.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement